Dona, 750 mg 60 pcs

DONA ® has anti-inflammatory and analgesic effect, fills the endogenous deficit of glucosamine, stimulates the synthesis of proteoglycans and hyaluronic acid synovial fluid; increases the permeability of the joint capsule, restores the enzymatic processes in the cells of synovial membrane and articular cartilage.

It promotes sulfur fixation in the synthesis of chondroitinous acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.

Pharmacokinetics

Absorption in the gastrointestinal tract 90%, bioavailability 25%, half-life – 70 hours.

Indications

Osteoarthrosis of peripheral joints and spine, osteochondrosis.

Pharmacological effect

DONA® has an anti-inflammatory and analgesic effect, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans of articular cartilage and hyaluronic acid of synovial fluid, thereby stimulating the regeneration of cartilage tissue; increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. Promotes fixation of sulfur during the synthesis of chondroitinsulfuric acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain. The effectiveness of glucosamine sulfate has been proven within 2-3 weeks from the start of use, and the duration of the effect ranges from 6 months to 3 years, in contrast to non-steroidal anti-inflammatory drugs (NSAIDs). Daily continuous treatment with glucosamine sulfate for 3 years showed progressive improvement in symptoms and a delay in joint structural changes, as determined by plain radiography. Glucosamine sulfate has demonstrated good tolerability in both short and long courses of treatment.

Absorption in the gastrointestinal tract is 90%, bioavailability is 25%, half-life is 70 hours.

Special instructions

When using the drug in patients with impaired glucose tolerance, with severe liver and kidney failure, medical supervision is required.
It is not recommended for children under 18 years of age due to the lack of scientific data for this category of patients.
The risk of allergic reactions increases with seafood intolerance.

Active ingredient

Glucosamine

Composition

One tablet contains:

active ingredient: glucosamine sulfate sodium chloride 942 mg (equivalent to glucosamine sulfate 750 mg and sodium chloride 192 mg);

excipients: microcrystalline cellulose (type 101) 68 mg, povidone K 25 (polyvinylpyrrolidone K 25) 45 mg, croscarmellose sodium 20 mg, macrogol 6000 (polyethylene glycol 6000) 15 mg, magnesium stearate 8.50 mg, talc 1.50 mg; shell: methacrylic acid and methyl methacrylate copolymer [1:1] (Eudragit L 12.5) 1.0 mg, crushed titanium dioxide 11.50 mg, talc 10.55 mg, methyl methacrylate, trimethylammonioethyl methacrylate chloride and ethyl acrylate copolymer [2:0.2:1] (Eudragit RL 30 D) 4.50 mg, triacetin (glycerol triacetate) 0.90 mg, macrogol 6000 (polyethylene glycol 6000) 0.55 mg.

Pregnancy

The use of the drug during pregnancy and breastfeeding is contraindicated due to the lack of scientific clinical data in this category of patients.

Contraindications

Individual hypersensitivity to the active substance and other components of the drug, severe chronic renal failure. It is not recommended to prescribe the drug during pregnancy and breastfeeding, as well as in childhood (under 18 years of age) due to the lack of scientific clinical data in this category of patients.

Side Effects

The incidence of side effects is determined as follows:
Very often: > 1/10;
Often: 1/100;
Uncommon: 1/1000;
Rare: 1/10000;
Very rare: < 1/10000;
Frequency unknown.
The most common adverse reactions associated with oral administration are nausea, abdominal pain, dyspepsia, flatulence, constipation and diarrhea. The adverse reactions described are usually mild and transient.
Immune system disorders:
Frequency unknown – allergic reactions (hypersensitivity).
Metabolic and nutritional disorders:
Frequency unknown – inadequate diabetes control.
Nervous system disorders:
Often – headache, drowsiness;
Frequency unknown – insomnia, dizziness.
Gastrointestinal disorders:
Often – diarrhea, constipation, nausea, flatulence, abdominal pain, dyspepsia; Frequency unknown – vomiting.
Skin and subcutaneous tissue disorders:
Uncommon: erythema, itching, rash;
Frequency unknown – angioedema, urticaria.
Hepatobiliary system disorders:
Frequency unknown – jaundice.
Sensory organ disorders:
Frequency unknown – visual impairment.
Respiratory system disorders:
Frequency unknown – asthma/exacerbation of asthma.
Cardiovascular system disorders:
Uncommon – hot flashes;
Frequency unknown – cardiac arrhythmia, tachycardia.
General violations:
Often – fatigue;
Frequency unknown – edema/peripheral edema.
Research:
Increased liver enzymes;
Increased blood glucose levels;
Increased blood pressure.
Cases of hypercholesterolemia have been reported, but a causal relationship has not been established.

Interaction

Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increases the absorption of tetracyclines, reduces the absorption of semisynthetic penicillins, chloramphenicol; enhances the effect of coumarin anticoagulants. When used together with non-steroidal anti-inflammatory drugs, it enhances the anti-inflammatory and analgesic effect of the latter.

Overdose

Cases of overdose are unknown. Treatment: gastric lavage, symptomatic therapy.

Short product description

Pharmacotherapeutic group: tissue repair stimulator.

ATX code: M01AX05.

Storage conditions

Store at a temperature not exceeding 25 ºC.
Keep out of the reach of children.

Shelf life

3 years.
Do not use after the expiration date indicated on the package.

Manufacturer

Madaus GmbH, Germany